A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer
Clinical trial NCT04866017 · TERMINATED
Trial details
- NCT number
- NCT04866017
- Sponsor
- BeiGene
- Status
- TERMINATED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-06-17
- Primary completion
- 2023-10-17
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.